KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Novartis Ag (NVS) Enterprise Value (2016 - 2026)

Novartis Ag's Enterprise Value history spans 15 years, with the latest figure at -$2.3 billion for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 0.89% to -$2.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.3 billion, a 0.89% decrease, with the full-year FY2025 number at -$2.3 billion, down 0.89% from a year prior.
  • Enterprise Value hit -$2.3 billion in Q4 2025 for Novartis Ag, down from -$12.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for NVS hit a ceiling of $156.0 million in Q3 2021 and a floor of -$28.3 billion in Q4 2021.
  • Historically, Enterprise Value has averaged -$5.8 billion across 5 years, with a median of -$644.0 million in 2023.
  • Biggest five-year swings in Enterprise Value: skyrocketed 3100.0% in 2021 and later plummeted 1392223.5% in 2022.
  • Tracing NVS's Enterprise Value over 5 years: stood at -$28.3 billion in 2021, then soared by 33.19% to -$18.9 billion in 2022, then grew by 23.8% to -$14.4 billion in 2023, then soared by 84.48% to -$2.2 billion in 2024, then decreased by 0.89% to -$2.3 billion in 2025.
  • Business Quant data shows Enterprise Value for NVS at -$2.3 billion in Q4 2025, -$12.0 million in Q3 2025, and -$11.4 billion in Q2 2025.